Our compounds act by reactivating the immune system shut down by tumors using a different mechanism from checkpoint inhibitor therapeutics
Our Executive Team coalesces over 75 years of experience from Financial, Medical, and Scientific areas of Biotechnology
Are you interested in helping to develop new technologies to diversify our ability to treat cancer?
Obtain a password and an NDA in order to obtain access to our scientific and financial documentation.
Copyright © 2020 BioMune, Inc. - All Rights Reserved.